The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Tariffs targeted at countries — reciprocal or regular — will likely be paid by multinational companies, dampening the outlook ...